9.74
+0(+0.00%)
Currency In USD
| Previous Close | 9.74 |
| Open | 9.4 |
| Day High | 10.27 |
| Day Low | 9.16 |
| 52-Week High | 47 |
| 52-Week Low | 7.65 |
| Volume | 73,882 |
| Average Volume | 99,503 |
| Market Cap | 144.23M |
| PE | -0.39 |
| EPS | -25 |
| Moving Average 50 Days | 9.05 |
| Moving Average 200 Days | 15.64 |
| Change | 0 |
If you invested $1000 in Lyell Immunopharma, Inc. (LYEL) since IPO date, it would be worth $28.83 as of June 15, 2025 at a share price of $9.74. Whereas If you bought $1000 worth of Lyell Immunopharma, Inc. (LYEL) shares 3 years ago, it would be worth $102.96 as of June 15, 2025 at a share price of $9.74.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
GlobeNewswire Inc.
Jun 09, 2025 8:05 PM GMT
Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vice-President
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
GlobeNewswire Inc.
Jun 04, 2025 8:05 PM GMT
SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, announced today that members of
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
GlobeNewswire Inc.
Apr 15, 2025 1:00 PM GMT
RMAT designation was granted based on promising clinical data from the ongoing Phase 1/2 trial of LYL314 in patients with relapsed and/or refractory large B-cell lymphoma.RMAT designation recognizes the potential of LYL314 to address significant unme